Table 2.
Incidence of euDKA within the first 30 days after surgery
| Discontinuation of SGLT2is for ≥ 3 days prior to surgery |
p-value | ||
|---|---|---|---|
| (+) (n = 627) | (−) (n = 542) | ||
| Development of perioperative euDKA | 1 (0.2) | 20 (3.7) | < 0.001 |
| Time to euDKA diagnosis | |||
| Within 3 days | 0 (0.0) | 9 (1.7) | < 0.001 |
| Within 7 days | 1 (0.2) | 16 (3.0) | |
| Within 14 days | 1 (0.2) | 19 (3.5) | |
| Within 30 days | 1 (0.2) | 20 (3.7) | |
| Predominant symptoms of euDKA | |||
| Nausea | 109 (17.4) | 113 (20.8) | 0.136 |
| Vomiting | 40 (6.4) | 38 (7.0) | 0.725 |
| Tachycardia | 1 (0.2) | 5 (0.9) | 0.102 |
| Abdominal pain | 0 (0.0) | 2 (0.4) | 0.215 |
| Postoperative laboratory parameters | |||
| Arterial pH | 7.44 [7.32–7.76] | 7.44 [7.27–7.55] | 0.580 |
| Serum bicarbonate level (mEq/L) | 25.0 [17.0–36.6] | 24.3 [11.7–33.1] | 0.013 |
| Serum BHBA level (µmol/L) | 35 [11–203] | 37 [12–574] | 0.629 |
| Blood glucose level (mg/dL) | 112 [68–257] | 112 [70–282] | 0.327 |
| Level of postoperative blood glucose | |||
| Hyperglycemia (≥ 125 mg/dL) | 167 (26.6) | 147 (27.1) | 0.895 |
| Mild hyperglycemia (125–250 mg/dL) | 158 (25.2) | 135 (24.9) | 0.946 |
| Hypoglycemia (≤ 60 mg/dL) | 0 (0.0) | 0 (0.0) | N.A. |
| Days until eating and SGLT2i are resumed after surgery | 1 [0–23] | 1 [0–24] | 0.614 |
Values are presented as median [range] or number (%). The data were analyzed using the Mann–Whitney U test or Fisher’s exact test. BHBA, β-hydroxybutyrate; euDKA, euglycemic diabetic ketoacidosis; N.A., not available; SGLT2i, sodium-glucose cotransporter 2 inhibitor